Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia

被引:17
|
作者
Ng, Kok Pin [1 ]
Chiew, Hui Jin [1 ]
Rosa-Neto, Pedro [2 ]
Kandiah, Nagaendran [1 ,3 ]
Ismail, Zahinoor [4 ,5 ,6 ,7 ]
Gauthier, Serge [2 ]
机构
[1] Natl Neurosci Inst, Dept Neurol, Singapore, Singapore
[2] McGill Univ, Res Ctr Studies Aging, Montreal, PQ, Canada
[3] Duke NUS Med Sch, Singapore, Singapore
[4] Univ Calgary, Hotchkiss Brain Inst, Dept Psychiat, Calgary, AB, Canada
[5] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB, Canada
[6] Univ Calgary, Hotchkiss Brain Inst, Dept Community Hlth Sci, Calgary, AB, Canada
[7] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
关键词
neuropsychiatric symptoms; Alzheimer's disease; metabolic dysfunction; F-18]fluorodeoxyglucose PET; mild behavioral impairment; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; BEHAVIORAL IMPAIRMENT; GLUCOSE-METABOLISM; FDG-PET; CACHE COUNTY; APATHY; RISK; DELUSIONS;
D O I
10.3389/fphar.2019.01398
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neuropsychiatric symptoms (NPS) including behavioral and psychiatric symptoms are common in the dementia stages of Alzheimer's disease (AD) and are associated with poorer outcomes in cognition, functional states, quality of life, and accelerated progression to severe dementia or death. NPS are also increasingly observed in the mild cognitive impairment stage of AD and may predict incipient dementia. As such, there is an emerging conceptual framework, which support NPS as early non-cognitive symptoms of dementia. [F-18]fluorodeoxyglucosepositron emission tomography is a technique that is sensitive in detecting resting metabolism associated with NPS in neuropsychiatric conditions, and there is a growing body of literature evaluating the role of NPS as early indicators of brain metabolic dysfunctions in AD. In this mini-review, we examine the frequency and associations of NPS with metabolic dysfunction in the AD continuum, including preclinical, prodromal, and dementia stages of AD. We will also present the validated neurobehavioral syndrome, mild behavioral impairment describes the later life emergence of sustained NPS as an at-risk state for incident cognitive decline and dementia, and an early presentation of neurodegenerative diseases in some. Lastly, we will discuss future directions in the field so as to better understand the neurobiological basis of NPS in the early stages of the AD continuum, and their role in predicting AD pathophysiological progression and incident dementia.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Neuropsychiatric symptoms in dementia-A role for neuroinflammation?
    Holmgren, Simon
    Hjorth, Erik
    Schultzberg, Marianne
    Larksater, Marie
    Frenkel, Dan
    Tysen-Backstrom, Ann Christine
    Aarsland, Dag
    Freund-Levi, Yvonne
    BRAIN RESEARCH BULLETIN, 2014, 108 : 88 - 93
  • [32] Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease
    Ng, Kok Pin
    Pascoal, Tharick A.
    Mathotaarachchi, Sulantha
    Chan, Yiong Huak
    Jiang, Lai
    Therriault, Joseph
    Benedet, Andrea L.
    Shin, Monica
    Kandiah, Nagaendran
    Greenwood, Celia M. T.
    Rosa-Neto, Pedro
    Gauthier, Serge
    Network, Dominantly Inherited Alzheimer
    TRANSLATIONAL NEURODEGENERATION, 2021, 10 (01)
  • [33] Greenness and neuropsychiatric symptoms in dementia
    Tondelli, Manuela
    Chiari, Annalisa
    Vinceti, Giulia
    Galli, Chiara
    Salemme, Simone
    Filippini, Tommaso
    Carbone, Chiara
    Minafra, Claudia
    De Luca, Claudia
    Prandi, Riccardo
    Tondelli, Simona
    Zamboni, Giovanna
    ENVIRONMENTAL RESEARCH, 2024, 242
  • [34] Improving environmental interventions for neuropsychiatric symptoms in dementia
    Kiosses, Dimitris N.
    Rosenberg, Paul B.
    INTERNATIONAL PSYCHOGERIATRICS, 2019, 31 (08) : 1077 - 1080
  • [35] Neuropsychiatric symptoms and ApoE genotype in older adults without dementia: a cross-sectional study
    Stella, Florindo
    Pais, Marcos Vasconcelos
    Loureiro, Julia Cunha
    Cordeiro, Augusto Magno Tranquezi
    Talib, Leda Leme
    Forlenza, Orestes Vicente
    PSYCHOGERIATRICS, 2024, 24 (02) : 382 - 390
  • [36] Neuropsychiatric symptoms and white matter hyperintensities in older adults without dementia
    Liampas, Ioannis
    Siokas, Vasileios
    Zoupa, Elli
    Kyriakoulopoulou, Panayiota
    Stamati, Polyxeni
    Provatas, Antonios
    Tsouris, Zisis
    Tsimourtou, Vana
    Lyketsos, Constantine G.
    Dardiotis, Efthimios
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 (11) : 1051 - 1063
  • [37] Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization
    Mar, Javier
    Arrospide, Arantzazu
    Soto-Gordoa, Myriam
    Iruin, Alvaro
    Tainta, Mikel
    Gabilondo, Andrea
    Mar-Barrutia, Lore
    Calvo, Montserrat
    Mateos, Maider
    Ibarrondo, Oliver
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 2027 - 2034
  • [38] Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA
    Maust, Donovan T.
    Langa, Kenneth M.
    Blow, Frederic C.
    Kales, Helen C.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 32 (02) : 164 - 174
  • [39] Neuropsychiatric Symptoms Associated With Frontotemporal Atrophy in Older Adults Without Dementia
    Liampas, Ioannis
    Siokas, Vasileios
    Stamati, Polyxeni
    Kyriakoulopoulou, Panayiota
    Tsouris, Zisis
    Zoupa, Elli
    Folia, Vasiliki
    Lyketsos, Constantine G.
    Dardiotis, Efthimios
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2024, 39 (12)
  • [40] Neuropsychiatric Symptoms and Cognitive Impairment: Understanding the Importance of Co-Morbid Symptoms
    Mortby, Moyra E.
    Burns, Richard
    Eramudugolla, Ranmalee
    Ismail, Zahinoor
    Anstey, Kaarin J.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 59 (01) : 141 - 153